MPN Horizons 2017 MPN 101 session CBC reading Dr. Martin Ellis

preview_player
Показать описание
MPN Horizons 2017 - Frankfurt Germany MPN 101 Session. Dr. Martin Ellis
  1. MPN Advocates Network
  2. MPN Horizons 2017
  3. MPN 101
Рекомендации по теме
MPN Horizons 2017 1:36:12

MPN Horizons 2017 MPN 101 session CBC reading Dr. Martin Ellis

To treat or 0:54:59

To treat or not to treat - MPN Horizons 2017

MPN Horizons 2019: 1:19:57

MPN Horizons 2019: MPN 101 Session with Dr. Martin Ellis

Change Your Prognosis 0:29:37

Change Your Prognosis Patients’ Involvement in Research - The Dutch experience

Australia – isolated 0:10:10

Australia – isolated by geography & population size- MPN Horizons 2017

MPN Horizons 2016: 0:36:35

MPN Horizons 2016: Advocacy session #4: Branding and marketing

MPN Hero Julie 0:03:16

MPN Hero Julie Libon: The Inspiration Behind HikeMF

The WHO Updated 0:25:48

The WHO Updated Diagnostic Criteria for MPN

Identifying risk factors 0:04:18

Identifying risk factors for thrombosis in MPNs and treatment strategies

Neues ECAD-Programm horizon 0:44:49

Neues ECAD-Programm horizon (GPN17)

Blood Cancer 101 0:50:49

Blood Cancer 101

Om Dansk MPN 0:01:27

Om Dansk MPN Forening

#AsktheMayoMom about Common 0:28:14

#AsktheMayoMom about Common Infections in Children and When to Worry It Could Be Something More

2 NCCN Guidelines 1:02:10

2 NCCN Guidelines & further updates Dr Martin Ellis

Leukopenia, Leukocytosis, Leukemias 0:50:02

Leukopenia, Leukocytosis, Leukemias and Myeloproliferative Disorders

Myeloproliferative neoplasms MPN 0:52:46

Myeloproliferative neoplasms MPN

CLL HORIZONS 2019 0:39:03

CLL HORIZONS 2019 - ORGANISATIONAL SUSTAINABILITY - AN ESTABLISHED PATIENT GROUP'S PRIORITIES

Myeloproliferative Disorders/Neoplasms 1:36:35

Myeloproliferative Disorders/Neoplasms

Natural History and 0:33:14

Natural History and Heredity - Jerry L. Spivak, MD

Demonstração de Tecnologias 0:15:03

Demonstração de Tecnologias L2VPN com EVPN

Biomarkers and Molecular 0:29:51

Biomarkers and Molecular Abnormalities: What Do Patients Need to Know? Alison Moliterno, MD

10 Panel discussion 1:21:00

10 Panel discussion Research Process with Industry & Doctors

WISE Webinar 2017-03: 1:27:52

WISE Webinar 2017-03: Achieving Financial Independence with Ticket to Work and The ABLE Act

CML - Generic 0:08:25

CML - Generic TKI's medication

Комментарии
Автор

Great talk. I totally agree with his last statement. I think these diseases will be characterized by mutation first in the near future. As I have “ET”, but they found an extremely rare KIT r888q mutation of “unknown significance” as my only mutation. I am not convinced I have the same disease as jak2 ET or PV. My platelets are quite high, 1.2 mil, along with mild eosinophilia, 1300 absolute. Megakaryocytes were increased, odd shaped, and some were kinda small apparently with tons of granulocytes/eosinophils.

Gold